Market News & Trends
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA
Petros Pharmaceuticals, Inc. recently announces it has received positive feedback from the US FDA following the FDA’s informal review of Petros’ technology component for self-selection…
Alvotech & Teva Announce FDA Approval of Biosimilar to Stelara
Alvotech and Teva Pharmaceuticals recently announced the US FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment…
CordenPharma & GENEPEP Celebrate Strong Collaboration Leveraging Peptide Drug Substance Discovery & Clinical Development Expertise
CordenPharma and GENEPEP have recently celebrated 1 year of their fruitful partnership signed in 2023, which supports biotech companies with the development, discovery, and manufacturing…
Atossa Therapeutics & Quantum Leap Healthcare Announce Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib in Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative recently announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib…
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. recently announced its Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA, disclosed SAB has completed dosing the third cohort for SAB-142 with…
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators With Issuance of Patent
GRI Bio, Inc. recently announced the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled Prevention…
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis
Organovo Holdings, Inc. recently released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314…
Cresset Creates New Vice President Role to Lead its Artificial Intelligence Strategy
Cresset an innovative provider of solutions for CADD, DMTA efficiency, and contract research, has expanded its senior leadership team with the appointment of Cambridge Scientist…
New Drug Delivery System Developed by Hebrew University Researchers Simultaneously Delivers Diverse Therapeutic Agents in a Single Carrier
A new drug delivery system that overcomes previous limitations in delivering diverse therapeutic compounds in a single carrier has been developed by Hebrew University of…
Ocular Therapeutix Executive Chairman Becomes President & CEO
Ocular Therapeutix, Inc. recently announced Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer (CEO), and that Antony…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….